Unversity Medical Center Groningen Trials

Unversity Medical Center Groningen	Welcome, Profile Billing Logout

Unversity Medical Center Groningen

Welcome, Profile Billing Logout

4 Trials

2 Trials

Active Trials Industry lead sponsorIndustry collaborator

Export

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Huls, Gerwin G

AML21, NCT02172872 / 2014-001486-27: "InDACtion" vs "3+7" Induction in AML

Active, not recruiting

606

Europe, RoW

standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen

European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto

Acute Myeloid Leukemia (AML)

03/22

12/23

NCT05949125: Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

Recruiting

Europe

Cyclophosphamide (Non-IMP, Lymphodepletion), Fludarabine (Non-IMP, Lymphodepletion), R-TM123, R-TM123 is one component of the Allo-RevCAR01-T-CD123 treatment, Allo-RevCAR01-T, Allo-RevCAR01-T is one component of the Allo-RevCAR01-T-CD123 treatment

AvenCell Europe GmbH, Allucent (NL) BV

Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory

05/27

01/28